Via DHC →
This month, DHC’s Executive Director, Christine Franklin, had the opportunity to interview Healthline’s SVP Sales & DTC Strategy, Brendan McHenry. This conversation focused on understanding what Healthline has learned about consumer behavior during COVID-19 and how they have been able to draw insights from trends in that behavior. Brendan also reviews the impact of consumer trends on pharma marketing and what marketers should do next.
Read The Interview →
Via PatientPoint →
PatientPoint is going directly to the source—doctors and patients—to gather insights about their attitudes and behaviors about COVID-19 and how the virus is affecting their delivery of and dependence on healthcare. The independent research, commissioned by PatientPoint through L Catterton and in collaboration with the National Foundation for Infectious Diseases, is intended to provide an ongoing benchmark of real doctor and patient insights on COVID-19.
Read Now →
Via WEGO Health and DHC →
WEGO Health partnered with the Digital Health Coalition to present a webinar on patient communities' perceptions of pharmaceutical advertising during the unprecedented times we face due to the impact of COVID-19. Now available on-demand: exclusive new findings from a survey of over 150 patient influencers across more than 80 condition areas with a discussion led by a panel of both Patient Leaders and key pharma industry stakeholders.
Watch On-Demand →
Via CMI/Compas →
CMI/Compas has published their latest insights in a two-part series of reports that update on the company’s studies of both Consumer and HCP audiences during COVID-19 outbreak and now recovery. The reports are based on new survey data of both audiences, with actionable recommendations from CMI/Compas media experts.
Individual Report Downloads Available →
Via Sermo →
The Sermo HCP Sentiment Series was created to better understand how COVID-19 is impacting the medical community and identify new ways our Industry partners can support healthcare professionals during these changing times. In Part III, Sermo explores physician perspectives on the timeline for returning to “normal” patient activity levels, and in turn, the impact on HCP access for pharmaceutical and medical technology companies moving forward.
Access the Details →
Via Crossix →
After nearly three months of restrictions to help prevent the spread of COVID-19, most of the country has started to re-open, and people are emerging from their lockdowns. In order to help pharmaceutical companies assess their strategies, Crossix has been monitoring country-wide health and media behaviors through the Crossix Data Platform.
Access the Infographics →
September 23/24, 12:00 - 1:30 eastern
The DHC, with host Novartis, is converted the originally scheduled East Coast Summit to a virtual event. The September 23/24 online summit will feature research highlights, case studies, thought leader POVs and panel discussions with key stakeholders addressing the opportunities and challenges of "the new normal".
Save the Date →